Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials.

BACKGROUND Increasingly, people living with human immunodeficiency virus (HIV) benefit from lower drug regimens (LDRs). Exploring viral genital shedding during LDRs is crucial to ensure their safety. METHODS We pooled genital sub-studies from 2 clinical trials in this area. Patients were randomized 1:1 to continue abacavir/lamivudine/dolutegravir or switch to dolutegravir (MONCAY trial), or to continue tenofovir/emtricitabine + a third agent or switch to tenofovir/emtricitabine (TRULIGHT trial). Participants whose plasma HIV-RNA remained <50 copies/mL had sperm or cervicovaginal lavage collected between Weeks 24 and 48. HIV-RNA and HIV-DNA were amplified by ultrasensitive polymerase chain reaction. The main objective was to measure the proportion of participants who had no detectable HIV in genital fluids, both according to each strategy and then in an aggregated analysis (LDR versus triple therapies). RESULTS There were 64 participants (35 males, 29 females) included: 16 received dual therapies and 16 received triple therapies in TRULIGHT; and 16 received monotherapies and 16 received triple therapies in MONCAY. In TRULIGHT, 13/15 (87%) of evaluable participants on dual therapy had no detectable HIV in their genital fluid, versus 14/15 (93%) under triple therapy (P = 1.0). In MONCAY, these figures were 12/15 (80%) on monotherapy versus 13/16 (81%) on triple therapy (P = 1.0). In the pooled analysis, a similar proportion of participants in the LDR and triple therapy groups had no detectable HIV: 25/30 (83%) and 27/31 (87%), respectively (P = .73). CONCLUSIONS There was no evidence of increased HIV-RNA and/or -DNA shedding in the genital fluids of people who maintained undetectable plasma HIV-RNA during LDRs.

[1]  Robert W Eisinger,et al.  HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. , 2019, JAMA.

[2]  B. Autran,et al.  Dynamics in HIV‐DNA levels over time in HIV controllers , 2019, Journal of the International AIDS Society.

[3]  C. Fichtenbaum,et al.  Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy , 2018, Journal of acquired immune deficiency syndromes.

[4]  C. Rouzioux,et al.  A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level , 2017, Open forum infectious diseases.

[5]  J. Castilla,et al.  Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients , 2016, PloS one.

[6]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[7]  R. SantosJosé,et al.  Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. , 2016 .

[8]  T. Hallett,et al.  Future challenges for clinical care of an ageing population infected with HIV: a modelling study , 2015, The Lancet. Infectious diseases.

[9]  J. Overbaugh,et al.  The role of cell-associated virus in mother-to-child HIV transmission. , 2014, The Journal of infectious diseases.

[10]  M. Sagar Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. , 2014, The Journal of infectious diseases.

[11]  A. Lazzarin,et al.  Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. , 2014, The Journal of antimicrobial chemotherapy.

[12]  B. Hirschel,et al.  HIV-1 Genital Shedding in HIV-Infected Patients Randomized to Second-Line Lopinavir/Ritonavir Monotherapy versus Tenofovir/Lamivudine/Lopinavir/ Ritonavir , 2014, Antiviral therapy.

[13]  C. Rouzioux,et al.  HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Y. Yazdanpanah,et al.  Timing of Intermittent Seminal HIV-1 RNA Shedding in Patients with Undetectable Plasma Viral Load under Combination Antiretroviral Therapy , 2014, PloS one.

[15]  C. Rouzioux,et al.  HIV-DNA in the Genital Tract of Women on Long-Term Effective Therapy Is Associated to Residual Viremia and Previous AIDS-Defining Illnesses , 2013, PloS one.

[16]  C. Charpentier,et al.  Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study , 2011, Antiviral therapy.

[17]  L. Panzeri,et al.  HIV shedding in cervico-vaginal secretions in pregnant women. , 2011, Current HIV Research.

[18]  J. Mullins,et al.  Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission , 2011, Science Translational Medicine.

[19]  P. Kissinger,et al.  Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. , 2010, The Journal of infectious diseases.

[20]  J. Hogan,et al.  Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load , 2010, AIDS.

[21]  H. Günthard,et al.  Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir , 2010, AIDS.

[22]  V. Calvez,et al.  Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy , 2010, Antimicrobial Agents and Chemotherapy.

[23]  M. Schechter,et al.  Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study) , 2009, HIV clinical trials.

[24]  Avettand‐Fènoël Véronique,et al.  LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .

[25]  C. Rouzioux,et al.  Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. , 2008, The Journal of antimicrobial chemotherapy.

[26]  P. Vernazza,et al.  The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial , 2007, AIDS.

[27]  J. Mellors,et al.  Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. , 2006, JAMA.

[28]  W. Blattner,et al.  Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. , 2003, The Journal of infectious diseases.

[29]  P. Vernazza,et al.  Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV , 2000, AIDS.

[30]  L. Bélec,et al.  Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays , 1995, Clinical and diagnostic laboratory immunology.

[31]  P. Viciana,et al.  Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  S. Alavian,et al.  Hepatitis delta virus facilitates the selection of hepatitis B virus mutants in vivo and functionally impacts on their replicative capacity in vitro. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.